Rationally designed viruses for use as vaccines or solid tumor therapies
Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.
Target customized oncolytics to treat primary tumors and shrink off-site metastases
177,000
RSV hospitalizations among adults 65+ no vaccine
48.8 million
Flu cases in 2017-18, current vaccines <37% effective
1 in 8
US women (about 12%) will develop invasive breast cancer during lifetime.
Our breakthrough approach to live-attenuated virus design
1. Recode
2. Synthesize
3. Transfect
4. Recover
-
April 23, 2019
Codagenix Inc. Announces Award of $1M US Army Contract for Continued Development of Contemporary, Balanced Dengue Vaccine
Farmingdale, New York, April 24, 2019 – Codagenix, Inc., announces today the awarding of a U.S. Department of Defense (DOD) Phase II SBIR contract to continue the development and testing of a live attenuated, quadrivalent vaccine against Dengue virus (DENV) – based on contemporary strains of Dengue virus.
Full Story -
March 01, 2019
Codagenix: Combating Deadly Diseases with a Fast Track to Vaccine Development
Future worldwide outbreaks of the Zika virus — as well as other widespread infections like flu, dengue, and E. coli — may soon be slowed or even stopped in their tracks, thanks to a rapid vaccine development process created by a biotech start-up on Long Island, NY.
Full Story